Evidence map›Paper›PMID 26632326›Full record

ArticleThe Journal of infection2016

Population tailored modification of tuberculosis specific interferon-gamma release assay.

Kata Horvati, Szilvia Bősze, Hannah P Gideon, Bernadett Bacsa, Tamás G Szabó, Rene Goliath, Molebogeng X Rangaka, Ferenc Hudecz, Robert J Wilkinson, Katalin A Wilkinson

Open access · hybridAbstract read

PubMed Full text at PMC Publisher

In one paragraph

Article in The Journal of infection, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it

0cells of the map it votes in

10citing papers in PubMed

1.4field-weighted citation impact, top 19% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

Antiretroviral Treatment-Induced Decrease in Immune Activation Contributes to Reduced Susceptibility to Tuberculosis in HIV-1/Mtb Co-infected Persons.Frontiers in immunology · 2021
Trial
Recent advances in the detection of interferon-gamma as a TB biomarker.Analytical and bioanalytical chemistry · 2022
Review
Differential Diagnosis of Latent Tuberculosis Infection and Active Tuberculosis: A Key to a Successful Tuberculosis Control Strategy.Frontiers in microbiology · 2021
Review
TNF-α antagonists differentially induce TGF-β1-dependent resuscitation of dormant-like Mycobacterium tuberculosis.PLoS pathogens · 2020
Article
Tuberculosis Antigen-Specific T-Cell Responses During the First 6 Months of Antiretroviral Treatment.The Journal of infectious diseases · 2020
Article
Quantitative Prediction of the Landscape of T Cell Epitope Immunogenicity in Sequence Space.Frontiers in immunology · 2019
Article
The effect of antiretroviral treatment on selected genes in whole blood from HIV-infected adults sensitised by Mycobacterium tuberculosis.PloS one · 2018
Article
Identification and evaluation of the novel immunodominant antigen Rv2351c from Mycobacterium tuberculosis.Emerging microbes & infections · 2017
Article
The bacillary and macrophage response to hypoxia in tuberculosis and the consequences for T cell antigen recognition.Microbes and infection · 2017
Review
Highly Multiplexed Proteomic Analysis of Quantiferon Supernatants To Identify Biomarkers of Latent Tuberculosis Infection.Journal of clinical microbiology · 2017
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Kata HorvatiMTA-ELTE Research Group of Peptide Chemistry, Eötvös L. University, Budapest, Hungary.

Szilvia BőszeMTA-ELTE Research Group of Peptide Chemistry, Eötvös L. University, Budapest, Hungary.

Hannah P GideonClinical Infectious Disease Research Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.

Bernadett BacsaMTA-ELTE Research Group of Peptide Chemistry, Eötvös L. University, Budapest, Hungary.

Tamás G SzabóDepartment of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary; Department of Laboratory Medicine, Semmelweis University, Budapest, Hungary.

Rene GoliathClinical Infectious Disease Research Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.

Molebogeng X RangakaClinical Infectious Disease Research Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.

Ferenc HudeczMTA-ELTE Research Group of Peptide Chemistry, Eötvös L. University, Budapest, Hungary; Department of Organic Chemistry, Eötvös L. University, Budapest, Hungary.

Robert J WilkinsonClinical Infectious Disease Research Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa; The Francis Crick Institute Mill Hill Laboratory, London NW7 1AA, UK; Department of Medicine, Imperial College London W2 1PG, UK.

Katalin A WilkinsonClinical Infectious Disease Research Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa; The Francis Crick Institute Mill Hill Laboratory, London NW7 1AA, UK. Electronic address: katalin.wilkinson@uct.ac.za.

University of Cape Town · ZAEötvös Loránd University · HUSemmelweis University · HU

Funding

Medical Research Council U.1175.02.002.00014.01Wellcome Trust 081667Wellcome Trust 104803

6 · The paper itself

Abstract

objectivesBlood-based Interferon-Gamma Release Assays (IGRA) identify Mycobacterium tuberculosis (MTB) sensitisation with increased specificity, but sensitivity remains impaired in human immunodeficiency virus (HIV) infected persons. The QuantiFERON-TB Gold In-Tube test contains peptide 38-55 of Rv2654c, based on data indicating differential recognition between tuberculosis patients and BCG vaccinated controls in Europe. We aimed to fine map the T cell response to Rv2654c with the view of improving sensitivity.

methodsInterferon-gamma ELISpot assay was used in HIV uninfected persons with latent and active tuberculosis to map peptide epitopes of Rv2654c. A modified IGRA was tested in two further groups of 55 HIV uninfected and 44 HIV infected persons, recruited in South Africa.

resultsThe most prominently recognised peptide was between amino acids 51-65. Using p51-65 to boost the QuantiFERON-TB Gold In-Tube assay, the quantitative performance of the modified IGRA increased from 1.83 IU/ml (IQR 0.30-7.35) to 2.83 (IQR 0.28-12.2; p = 0.002) in the HIV uninfected group. In the HIV infected cohort the percentage of positive responders increased from 57% to 64% but only after 3 months of ART (p = ns).

conclusionsOur data shows the potential to population tailor detection of MTB sensitization using specific synthetic peptides and interferon-gamma release in vitro.

Indexed as

AdultAntigens, BacterialEnzyme-Linked Immunospot AssayEpitope MappingEpitopes, T-LymphocyteEuropeFemaleHIV InfectionsHumansInterferon-gamma Release TestsMaleSensitivity and SpecificitySouth AfricaTuberculosisAntigens, BacterialEpitopes, T-LymphocyteRv2654 protein, Mycobacterium tuberculosisHIVInterferon-Gamma Release Assays (IGRA)Peptide epitopeQuantiFERON assayRv2654cTuberculosis

Identifiers

PMID26632326

DOI10.1016/j.jinf.2015.10.012

PMCPMC4747975

OpenAlexW2180356877

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.